Researchers find losartan is not effective in reducing hospitalization from mild COVID-19
The common blood pressure medication also does not appear to have any significant harmful side effects on patients with COVID-19
Published 2021-06-18 · Original archive entry · Explore research explainers
MINNEAPOLIS/ST. PAUL (06/18/2021) -- University of Minnesota Medical School researchers determined that the common blood pressure medication, losartan, is not effective in reducing hospitalization for mildly-ill COVID-19 outpatients.
In the multicenter, randomized, double-blinded clinical trial, non-hospitalized patients recently diagnosed with COVID-19 were given either losartan or a placebo and monitored for 15 days. The study's results, which were published in END
In the multicenter, randomized, double-blinded clinical trial, non-hospitalized patients recently diagnosed with COVID-19 were given either losartan or a placebo and monitored for 15 days. The study's results, which were published in END